BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Chemcon Speciality Chemicals Ltd. is the only manufacturer of HMDS (hexamethyldisilazane) in India and third largest globally.
It is also the largest player of CMIC (Chloromethyl Isopropyl Carbonate) in India and second largest worldwide.
Additionally, Chemcon Speciality is the only manufacturer of Zinc Bromide and the largest of Calcium Bromide in India.
40% of the revenues come from export which has grown at a compound annual growth rate of 18% over FY18-20.
The Company enjoys high entry barriers which leads to client stickiness and long standing relationships.
Issue Size: The Rs 3.2 billion IPO consists of fresh issue of Rs 1.7 billion and offer for sale (4.5 million shares by promoter) of Rs 1.5 billion which would result in promoter’s stake reducing from 100% pre-IPO to 74.5% post-IPO.
The funds raised from fresh issue will be utilized to fund capex, meet working capital requirements and for general corporate purpose.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR